Hisamitsu Pharmaceutical Co., Inc.

4530

JP3784600003

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
3,779 ^JPY	+1.86%		+0.13%	-12.34%

Apr. 11	Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024	MT
Jan. 12	Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise	MT

Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on October 12, 2022.

February 13, 2023 at 01:00 am EST

From October 12, 2022 to February 10, 2023, the company has repurchased 2,000,000 shares, representing 2.51% for ¥7,693.05 million. With this, the company has completed the repurchase of 2,000,000 shares, representing 2.51% for ¥7,693.05 million under the buyback announced on October 12, 2022.

Latest news about Hisamitsu Pharmaceutical Co., Inc.

Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024	Apr. 11	MT
Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise	Jan. 12	MT
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024	Jan. 11	CI
Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024	Jan. 11	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	Dec. 26	CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on July 13, 2023, has closed with 2,000,000 shares, representing 2.58% for ¥9,792.58 million.	Dec. 24	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	Dec. 05	CI
Hisamitsu Pharmaceutical’s Attributable Profit up 29.4% in Fiscal Q2 on Improved Net Sales	23-10-08	MT
Hisamitsu Pharmaceutical Co., Inc. Reports Earnings Results for the Half Year Ended August 31, 2023	23-10-06	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	23-09-04	CI
Hisamitsu Pharmaceutical Attributable Profit More Than Doubles in Fiscal Q1; Shares Climb 11%	23-07-13	MT
Hisamitsu Pharmaceutical Co., Inc. announces an Equity Buyback for 2,000,000 shares, for ¥10,000 million.	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2024 and Full Year Ending February 29, 2024	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. authorizes a Buyback Plan.	23-07-12	CI
Hisamitsu Pharmaceutical Affirms Final Dividend on Higher FY23 Profit, Revenue	23-04-14	MT
Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Year 2023, Effective May 26, 2023	23-04-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2024 and Full Year Ending February 29, 2024	23-04-13	CI
Hisamitsu Pharmaceutical Co., Inc. Announces Special Dividend for the Fiscal Year 2023	23-04-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 29, 2024	23-04-13	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on October 12, 2022.	23-02-13	CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on October 12, 2022, has closed with 2,000,000 shares, representing 2.51% for ¥7,693.05 million.	23-02-09	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023	23-01-12	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Special Dividend Guidance for the Fiscal Year 2023	23-01-12	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Year End Dividend Guidance for the Fiscal Year Ending February 28, 2023	23-01-12	CI

Chart Hisamitsu Pharmaceutical Co., Inc.

Duration

Period

Chart Hisamitsu Pharmaceutical Co., Inc.

More charts

Company Profile

Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.

Sector

Pharmaceuticals

Calendar

2024-07-03 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hisamitsu Pharmaceutical Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,779 JPY

Average target price

3,950 JPY

Spread / Average Target

+4.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HISAMITSU PHARMACEUTICAL CO., INC.	-12.34%	1.82B
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Other Pharmaceuticals

Hisamitsu Pharmaceutical Co., Inc.

Equities

4530

JP3784600003

Pharmaceuticals

Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on October 12, 2022.

EPS Revisions